(Total Views: 661)
Posted On: 03/25/2022 2:06:38 PM
Post# of 148878
The new Seeking Alpha article about long COVID that mentions CYDY is a big nothing. Clearly it's clickbait to get ad revenue. Here's the paragraph that mentions CYDY, in the context of "gee, there's such a thing as long COVID, and some companies are studying treatments."
Again, it's an airball. I hated having to give them the revenue from clicking on it.
At least they didn't bash it, like they usually do. I guess the snotty "according to the company" was felt to be sufficient. Here's the link if you want to support their short-selling site.
https://seekingalpha.com/news/3817601-long-co...2312.53185
Again, it's an airball. I hated having to give them the revenue from clicking on it.
Quote:
Other developers working on long COVID therapeutics include CytoDyn (OTCQB:CYDY), AIM ImmunoTech (AIM), NLS Pharmaceutics (NLSP), Axcella Health (AXLA), and Tonix Pharmaceuticals (TNXP).
In June, CytoDyn (OTCQB:CYDY) shared interim data from its COVID-19 long-haulers clinical trial, which, according to the company, showed an improvement of most of the symptoms compared to a placebo.
At least they didn't bash it, like they usually do. I guess the snotty "according to the company" was felt to be sufficient. Here's the link if you want to support their short-selling site.
https://seekingalpha.com/news/3817601-long-co...2312.53185
(2)
(0)Scroll down for more posts ▼
